Enveric Biosciences (ENVB) Return on Capital Employed Growth (1y) (2012 - 2026)
Enveric Biosciences (ENVB) Return on Capital Employed Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 45.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -785.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,629.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3,193.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 399.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -310.00 |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 19,943.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,172.00 |
| Dec 31, 2025 | 16,342.00 |
| Sep 30, 2025 | -12,688.00 |
| Jun 30, 2025 | -18,643.00 |
| Mar 31, 2025 | 1,306.00 |
| Dec 31, 2024 | 13,418.00 |
| Sep 30, 2024 | 46,072.00 |
| Jun 30, 2024 | 21,108.00 |
| Mar 31, 2024 | -12,717.00 |
| Dec 31, 2023 | -39,860.00 |
| Sep 30, 2023 | -40,981.00 |
| Jun 30, 2023 | -13,293.00 |
| Mar 31, 2023 | 2,187.00 |
| Dec 31, 2022 | 1,276.00 |
| Sep 30, 2022 | -20,539.00 |
| Jun 30, 2022 | -16,816.00 |
| Mar 31, 2022 | -14,838.00 |
| Dec 31, 2021 | -10,546.00 |
| Sep 30, 2021 | -3,816.00 |
| Jun 30, 2021 | -5,225.00 |